Document is current

Article History

Received: 19 December 2025

Accepted: 19 April 2026

First Online: 13 May 2026

Declarations

Conflict of interest: MP, TB, MY, MB, LW, JK, SJ, SA, JJ, TM, JGZ, and JC received honoraria for participation in the Genital Psoriasis Wellness Consortium. MG, RK, and CR received honoraria for reviewing the final consensus statements. MP has served as a consultant for AbbVie, Amgen, Apogee Therapeutics, Arcutis, BMS, Boehringer Ingelheim, Botanix, Castle Biosciences, Dermavant (Organon), Disc Medicine, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Nielsen BioSciences, Novartis, ONVIV, Ortho Dermatologics, Oruka, Pfizer, Regeneron, Sanofi-Genzyme, Sun Pharmaceuticals, Takeda, UCB, and VeraDermics; as a speaker for AbbVie, Amgen, Arcutis, BMS, Botanix, Dermavant (Organon), Galderma, Incyte, Janssen, Lilly, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, Sun Pharmaceuticals, and UCB; and an investigator for AbbVie, Cara Therapeutics, CorEvitas Atopic Dermatitis Registry, CorEvitas Psoriasis Registry, Dermavant (Organon), Dermira, Incyte, Lilly, Mindera, Novartis, Oruka, and Takeda. TB has received research funding from Amgen, Castle Biosciences, CorEvitas, Novartis, Pfizer, and Regeneron. She has served as an advisor for AbbVie, Arcutis, ASLAN Pharmaceuticals, BMS, Boehringer Ingelheim, Dermavant, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Pfizer, Novartis, Sanofi, Sun Pharma, Takeda, and UCB. She is a speaker for AbbVie, Amgen, Arcutis, BMS, Dermavant, Galderma, Janssen, LEO Pharma, Lilly, Ortho Dermatologics, Sanofi, and UCB. MY has received consulting fees from Arcutis, Dermavant, and Lilly; personal fees or honoraria for speakers bureaus from Arcutis and Dermavant; and serves as a board member for the Society of Dermatology Nurse Practitioners, which receives grants from Arcutis, Dermavant, and Lilly. MB has received consulting fees, personal fees, or honoraria for lectures, presentations, speakers bureaus, or educational events, and support for attending meetings and/or travel from Arcutis. LW reports no additional conflicts of interest. JK has received honoraria from AbbVie, Arcutis, AbbVie, Amgen, Castle Biosciences, Celltrion, Galderma, Janssen, Lilly, Sun Pharma, Regeneron/Sanofi, Pfizer, and UCB for being a speaker and/or an advisor. RF has received honoraria for lectures, presentations, speakers bureaus, educational events, or advisory boards from Almirall, Dermavant, and Sanofi. SJ has received honoraria for lectures, presentations, speakers bureaus, educational events, or advisory boards, investigator fees, or grants/research funding from AbbVie, Amgen, Arcutis, Arkansas College of Osteopathic Medicine, BioMetrix, BMS, Cara Therapeutics, Castle Biosciences, Concert Pharmaceuticals, Dermavant, Evidera, Galderma, Incyte, Innovaderm, Janssen, Kansas Foundation for Medical Care, LEO Pharma, Lilly, National Psoriasis Foundation, Nielsen BioSciences, Novartis, Regeneron, Sanofi, Takeda, TARGET Pharma, and University of Pennsylvania, and has received other financial benefit as the founder of Type IV Technologies. SA has received personal fees or honoraria for lectures, presentations, speakers bureaus, or educational events from Arcutis, LEO Pharma, Lilly, Maui Derm, Medscape, Peds 360, and the Permanente Medical Group; and support for attending meetings and/or travel from Maui Derm and MedScape. JJ has received consulting fees, personal fees, or honoraria for lectures, presentations, speakers bureaus, educational events, or advisory boards as well as support for attending meetings and/or travel from Arcutis; and has served as principal investigator for Amgen, Arcutis, and National Psoriasis Foundation and as a sub-investigator for Janssen. TM reports grants or contracts with payments to the University of Alabama at Birmingham from Acelyrin, BMS, ChemoCentryx, Galderma, Janssen, Lilly, and Pfizer; honoraria for consulting services from AbbVie, Arcutis, BMS, Bodewell, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Physician Education Resources (PER), and UCB; honoraria for participation on data safety monitoring boards or advisory boards from AbbVie, Arcutis, BMS, Bodewell, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, and UCB; and serves as a board member or editorial board member for the Association of Clinical Research Professionals (ACRP), the Southeastern Consortium for Dermatology, the Skin of Color Society, and the Journal of the American Academy of Dermatology . JZ has received compensation/honoraria from Dermavant, Ferndale Pharma Group, Janssen, Merck, and the Vaseline Healing Project, and serves as chair of the American Academy of Dermatology State Society Relationship Committee and the American Academy of Dermatology LGBTQ Expert Research Group. MS, DH, and KB are employees of Arcutis Biotherapeutics, Inc. JC has received consulting fees, personal fees, or honoraria for lectures, presentations, speakers bureaus, or educational events from AbbVie, Amgen, Arcutis, Dermavant, LEO Pharma, Lilly, and Pfizer.

Ethics approval: Ethics approval was not required as the nature of this work did not utilize any animal or human participants.

Consent to participate: Not applicable.

Consent for publication: Not applicable.

Availability of data and material: Not applicable.

Code availability: Not applicable.

Author contributions: All authors provided (i) substantial contributions to conception and design, or drafting the consensus statements through the modified Delphi process (JC, MY, MB, SA, TB, RF, JJ, SJ, JK, TM, MP, LW, JGZ, KB, MSS, and DH); (ii) drafting the article or revising it critically for important intellectual content; and (iii) final approval of the version to be published.